A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer

BACKGROUND: The mammalian target of rapamycin (mTOR) pathway is dysregulated in small-cell lung cancer (SCLC) and everolimus is an oral mTOR inhibitor. METHODS: This phase-1b study assessed everolimus safety at the levels of 2.5, 5, or 10 mg once daily in combination with paclitaxel (175 mg m(−2)) o...

Full description

Saved in:
Bibliographic Details
Main Authors: Sun, J M, Kim, J R, Do, I G, Lee, S Y, Lee, J, Choi, Y L, Ahn, J S, Ahn, M J, Park, K
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2013
Subjects:
Clinical Study
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3776982/
https://ncbi.nlm.nih.gov/pubmed/23963141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.467
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items